Kenya vs Ukraine: Average cost of multi drug-resistant tuberculosis treatment
Kenya
1,800 constant 2022 US$
in 2024
Ukraine
1,994 constant 2022 US$
in 2024
Kenya rank
26th
Ukraine rank
24th
Average cost of multi drug-resistant tuberculosis treatment over time
- Kenya
- Ukraine
How they compare
Ukraine currently reports 1,994 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya, a difference of 194 constant 2022 US$.
That makes Ukraine's figure about 1.1 times Kenya's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Kenya ahead.
Kenya ranks 26th and Ukraine ranks 24th of 92 countries.
Across the 2 decades both report, Kenya averaged higher in 1 and Ukraine in 1.
Head to head by decade
| Decade | Kenya | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,883 constant 2022 US$ | 1,731 constant 2022 US$ | 1,152 constant 2022 US$ | Kenya |
| 2020s | 1,706 constant 2022 US$ | 2,144 constant 2022 US$ | 438 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Kenya or Ukraine?
- Ukraine, at 1,994 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Kenya and Ukraine?
- 194 constant 2022 US$, with Ukraine ahead.
- How many years of comparable data are there for Kenya and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Ukraine rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Kenya ranks 26th and Ukraine ranks 24th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.